MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 05-30-2026
Enzo Biochem Total Liabilities 2011-2026 | ENZ
Annual Total Liabilities Enzo Biochem
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.7 M | 43.4 M | 21.1 M | 45.1 M | 54.2 M | 20.6 M | 20.5 M | 18.8 M | 22.3 M | 25.8 M | 27.5 M | 24.8 M | 20 M | 20.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.2 M | 18.8 M | 28.2 M |
Quarterly Total Liabilities Enzo Biochem
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.1 M | 20.9 M | 27.6 M | 27.6 M | 29.7 M | 24.4 M | 28.3 M | 32 M | 43.4 M | 53.1 M | 43.7 M | 40.2 M | 41.4 M | 41.7 M | 50.2 M | 41.4 M | 45.1 M | 45.1 M | 45.9 M | 54.5 M | 54.2 M | 54.2 M | 21.6 M | 46.9 M | 20.6 M | 20 M | 20.4 M | 18.5 M | 20.5 M | 20.5 M | 18.7 M | 20.1 M | 18.8 M | 18.8 M | 26.5 M | 22 M | 22.3 M | 22.3 M | 24.7 M | 27.2 M | 25.8 M | 25.8 M | 23.5 M | 26.5 M | 27.5 M | 27.5 M | - | 25.2 M | 24.8 M | 24.8 M | - | 20 M | 20 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.5 M | 18.5 M | 30.3 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B |  USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 202.18 | -0.43 % | $ 22.4 B | USA |
 |
Celcuity
CELC
|
366 M | $ 88.24 | -0.35 % | $ 4.13 B | USA |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 3.78 | -11.89 % | $ 5.03 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 18.35 | -1.77 % | $ 565 M | USA |
 |
Castle Biosciences
CSTL
|
108 M | $ 20.66 | -0.19 % | $ 599 M | USA |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
84.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
2.11 B | $ 129.82 | -1.37 % | $ 16.3 B | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.58 | -1.56 % | $ 6.99 M | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 24.08 | 4.83 % | $ 1.28 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
Illumina
ILMN
|
2.7 B | $ 166.89 | 3.68 % | $ 25.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
7.08 B | $ 147.72 | 1.05 % | $ 11.6 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 154.47 | 2.03 % | $ 23.8 B |  Schweiz |
 |
Genetic Technologies Limited
GENE
|
4.36 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
National Research Corporation
NRC
|
121 M | $ 18.31 | -2.55 % | $ 410 M | USA |
 |
Natera
NTRA
|
686 M | $ 216.97 | 2.31 % | $ 29.7 B | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 104.67 | 0.14 % | $ 7.06 B | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 188.47 | 0.51 % | $ 9.34 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.32 | 0.76 % | $ 396 M | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 467.5 | 0.03 % | $ 13.5 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
NeoGenomics
NEO
|
523 M | $ 11.09 | -0.54 % | $ 1.42 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 4.32 | -0.23 % | $ 400 M | USA |
 |
Personalis
PSNL
|
73 M | $ 9.79 | 2.09 % | $ 874 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 26.69 | 0.87 % | $ 25.3 B |  Niderland |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 7.24 | 0.84 % | $ 302 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
114 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.0 | -2.44 % | $ 4.59 M | USA |
 |
Twist Bioscience Corporation
TWST
|
169 M | $ 80.79 | 6.07 % | $ 4.83 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 265.03 | -0.42 % | $ 22.1 B | USA |
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 473.72 | 1.03 % | $ 179 B | USA |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 0.68 | 4.18 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 9.3 | 2.2 % | $ 2.02 B | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |